SCHEMBL6318329

SCHEMBL6318329

COc1ccc(-c2noc(N)c2C(=O)NCc2ccco2)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.55
HSD17B10 Q99714 4/20 0.50
ALOX15 P16050 3/20 0.50
USP2 O75604 2/20 0.50
ALDH1A1 P00352 8/20 0.48
POLB P06746 5/20 0.47
MAPT P10636 4/20 0.47
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 3/20 0.47
MEN1 O00255 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
APEX1 P27695 1/20 0.47
RECQL P46063 1/20 0.47
BCL2L1 Q07817 1/20 0.47
MCL1 Q07820 1/20 0.47
RAB9A P51151 5/20 0.46
NPC1 O15118 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HPGD P15428 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324039 0.86 ALDH1A1 (0.52) TSHRHSD17B10ALDH1A1MAPTKMT2A
SCHEMBL6315898 0.85 GABRA1 (0.43) TSHRHSD17B10ALDH1A1POLBMAPT
SCHEMBL6315038 0.83 RAB9A (0.50) HSD17B10USP2ALDH1A1POLBMAPT
SCHEMBL6323905 0.83 NPC1 (0.52) ALDH1A1POLBMAPTKMT2AKDM4E
SCHEMBL6324368 0.83 MAPT (0.44) TSHRALDH1A1POLBMAPTKDM4E
SCHEMBL6316520 0.83 MAPT (0.52) TSHRALDH1A1POLBMAPTL3MBTL1
SCHEMBL6323365 0.83 CDK2 (0.47) ALDH1A1MAPTKMT2AMEN1RAB9A
SCHEMBL6317699 0.83 ALDH1A1 (0.45) TSHRALDH1A1POLBMAPTKMT2A
SCHEMBL6317197 0.83 LMNA (0.44) TSHRALDH1A1POLBMAPTTDP1
SCHEMBL6315275 0.83 NPC1 (0.48) TSHRALDH1A1POLBMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 TSHR 3971/4885HSD17B10 4152/4885ALOX15 2753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.